期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 96, 期 -, 页码 3-17出版社
ELSEVIER
DOI: 10.1016/j.addr.2015.05.004
关键词
Embryonic stem cells; Induced pluripotent stem cells; Cardiac regeneration; Cardiac repair; Heart failure; Cardiovascular disease; Drug discovery; Disease modeling
资金
- National Institutes of Health [R01-HL064387, P01-HL094374, U01-HL100405, R01-HL117991, U54-HG007010]
Human pluripotent stem cells (PSCs) represent an attractive source of cardiomyocytes with potential applications including disease modeling, drug discovery and safety screening, and novel cell-based cardiac therapies. Insights from embryology have contributed to the development of efficient, reliable methods capable of generating large quantities of human PSC-cardiomyocytes with cardiac purities ranging up to 90%. However, for human PSCs to meet their full potential, the field must identify methods to generate cardiomyocyte populations that are uniform in subtype (e.g. homogeneous ventricular cardiomyocytes) and have more mature structural and functional properties. For in vivo applications, cardiomyocyte production must be highly scalable and clinical grade, and we will need to overcome challenges including graft cell death, immune rejection, arrhythmogenesis, and tumorigenic potential. Here we discuss the types of human PSCs, commonly used methods to guide their differentiation into cardiomyocytes, the phenotype of the resultant cardiomyocytes, and the remaining obstacles to their successful translation. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据